Biotech Blues: Their Stocks Tank as Newly Public Firms Find Trouble
The urge to do an IPO was strong, and for some, much too early. Maybe staying private before maturing is a good idea for companies, especially biotech ones. That’s...
Tag: FDA
Gene Therapy: For Investors, a Source of Dreams—and Duds
Ingenious science, when it doesn’t pan out, can bring volatile stock performance.